Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P14410
UPID:
SUIS_HUMAN
Alternative names:
-
Alternative UPACC:
P14410; A2RUC3; Q1JQ80; Q1RMC2
Background:
Sucrase-isomaltase, an intestinal enzyme, plays a pivotal role in carbohydrate digestion, targeting alpha-1,4- and alpha-1,6-oligosaccharides. Its activity is crucial for the efficient breakdown of dietary sugars into absorbable units.
Therapeutic significance:
The enzyme's deficiency leads to Congenital sucrase-isomaltase deficiency (CSID), a disorder marked by fermentative diarrhea and abdominal pain upon sugar intake. Understanding the enzyme's function could pave the way for innovative treatments for CSID, enhancing life quality for affected individuals.